Astellas Pharma Europe Limited
Chertsey, England (ots/PRNewswire) - A new treatment, BETMIGA(TM) (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive bladder (OAB) symptoms in adults.[1] Mirabegron represents the first new class of oral treatment in OAB for over 30 years. Currently around half of patients discontinue OAB treatment after only three ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - - HGT Pipeline Enhanced with Protein Replacement Therapy Being Investigated for the Treatment of Dystrophic Epidermolysis Bullosa Shire plc , announces that it has signed an agreement to acquire Lotus Tissue Repair, Inc. of Cambridge, MA, a privately held biotechnology company developing the first and only protein replacement therapy currently being investigated for the ...
Hatfield, England (ots/PRNewswire) - Eisai today launches Fycompa(R) (perampanel) in Norway as a treatment for partial-onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.[1] Perampanel is the first in an entirely new class of treatment for uncontrolled partial epilepsy, the most common form of the ...
Geneva (ots/PRNewswire) - Merck Serono, a division of Merck, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) approved Rebif(R) Rebidose(R) (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). "Over the past two decades, ...
Hatfield, England (ots/PRNewswire) - Child friendly formulation set to aid administration for the treatment of Lennox-Gastaut syndrome Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in Spain. As many patients who receive the orphan ...
http://resources.euroadhoc.com/us/IPI4rsuU issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open ...
Marlow, England (ots/PRNewswire) - Data demonstrates BOTOX(R)injections can reduce urinary leakage episodes for up to six months in patients who have had an inadequate response to, or are intolerant of, anticholinergic medication Today, Allergan Inc. announced that BOTOX(R)has received a positive opinion from the ...
http://resources.euroadhoc.com/us/KN1K9flc issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Shire Pharmaceuticals Group Plc
Nyon, Switzerland (ots/PRNewswire) - Shire plc today announces a positive outcome from the European Decentralised Procedure (DCP) for Elvanse(R) (to be known as Tyvense(R) in Ireland). Elvanse is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children ...
Amsterdam (ots/PRNewswire) - Norgine BV (Amsterdam) and SpePharm Holding BV (Amsterdam) announced today that they have concluded a broad collaboration agreement under which the two companies have invested in a 50:50 joint venture, SpePharm AG, which has acquired the entire product portfolio of SpePharm Holding, including Savene(R), MuGard(R), Xerotin(R), PROther(R) and the Dantrium(R) brands. The new joint venture will ...
Raritan, New Jersey (ots/PRNewswire) - Veridex, LLC today announced approval from the China State Food & Drug Administration (SFDA) for the CellSearch(R) circulating tumor cell (CTC) test as an in vitro diagnostic for women with metastatic breast cancer. This makes CellSearch(R) the first and only approved CTC test for cancer patients in China, which is the seventh ...
Lausanne, Switzerland (ots/PRNewswire) - - Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms - Strong support from internal shareholders and a recognition of our achievements Biocartis, a molecular diagnostics company developing and commercializing innovative, high ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - My CML Life Online Resource Centre Empowers and Guides Patients with CML Through Different Stages of Their Journey Bristol-Myers Squibb Company today announced the introduction of "My CML Life", a disease awareness website for patients with chronic myeloid leukaemia (CML). In recognition of ...
Bologna, Italy And Amsterdam (ots/PRNewswire) - Alfa Wassermann and Norgine are pleased to announce that they have received European Marketing Authorisation for XIFAXAN(R) 550mg (rifaximin-alpha) / REFERO(R) / TARGAXAN(R) / TIXTELLER(R) in the reduction of recurrence of episodes of overt hepatic encephalopathy (HE) ...
http://resources.euroadhoc.com/us/fwg66J4J issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: ...
Lyon, France (ots/PRNewswire) - Data represents the largest follow-up available for an HPV vaccine Data from two large, long term follow-up studies continue to show that vaccination with Gardasil offers a long duration of protection from human papillomavirus (HPV) diseases related to HPV types 6, 11, 16 and 18. HPV-related diseases include cervical cancer and genital ...
Lausanne, Switzerland (ots/PRNewswire) - Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology ("DMAT"): - New proteomic and nucleic acid platform provides ultra-high quality data analysis even at higher multiplex formats. - Platform launched well ahead of plan. Biocartis flips from a late-stage development company into a commercial ...
Bagsværd, Denmark (ots/PRNewswire) - ? Novo Nordisk today announced a unique partnership to form Team Novo Nordisk, a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team. To view the Multimedia News Release, please click: ...
Cambridge, England (ots/PRNewswire) - - Total of 43 bendamustine abstracts to be presented at ASH, including five oral presentations - New data supports use of bendamustine-rituximab (B-R) regimen in indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) 43 abstracts, announcing the results of studies ...
http://resources.euroadhoc.com/us/vWhJG9vN issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Shire plc and Boston Children's Hospital today announced a three-year, broad research collaboration in rare diseases. The goal of the collaboration is to develop novel therapies to treat a number of rare pediatric diseases with high unmet medical need, thereby leveraging Boston Children's research expertise and Shire's ...
Ballerup, Denmark (ots/PRNewswire) - Today LEO Pharma announced that the European Commission (EC) has granted marketing authorisation for Picato(R) (ingenol mebutate) gel as a treatment for actinic keratosis in the European Union (EU). Picato(R) gel is a once-daily, two or three day field-directed topical treatment for actinic keratosis, a common skin condition which ...
Tokyo (ots/PRNewswire) - HOYA Corporation ("HOYA") today executed an agreement with Seiko Epson Corporation ("EPSON") on the transfer of Epson's eyeglass lens development and manufacturing to HOYA. The day of the transfer is planned for the 1st February 2013. HOYA also executed today an agreement with Seiko Holdings Corporation ("SEIKO") on the partial ownership of ...
Shire Pharmaceuticals Group Plc
Dublin (ots/PRNewswire) - - Fifteen everyday heroes who selflessly care for others in the face of adversity honored by Shire in annual international awards program They inspire with their determination, selflessness, courage and hope. Fifteen caregivers from around the world have been announced today as Recipients or Distinguished Honorees in the 2nd Annual Shire BRAVE Awards, an international program that honors the bravery and devotion of non-professional caregivers. ...
Düsseldorf, Germany (ots/PRNewswire) - BiPAP A40 is a new multi-modality bi-level ventilator featuring the first fully automatic ventilation mode, designed to support the smooth transition of treatment from hospital to home Philips Respironics today announces the availability of the new bi-level ventilator BiPAP ...
Berlin (ots/PRNewswire) - Not intended for U.S. and UK Media - 20,000-patient study will be conducted in collaboration with Population Health Research Institute - Composite of cardiovascular death, myocardial infarction and stroke as primary efficacy endpoint - Rivaroxaban is the first novel oral anticoagulant under ...
Boston, Massachusetts (ots/PRNewswire) - - Study presented at American Association for the Study of Liver Diseases 2012 shows high sustained virological response (SVR) in HCV/HIV co-infected patients receiving INCIVO(R) (telaprevir)-based regimen - Janssen Infectious Diseases-Diagnostics BVBA (Janssen) today ...
Ittigen, Switzerland (ots) - Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 ...
http://resources.euroadhoc.com/us/mdttPc7K http://resources.euroadhoc.com/us/Bi0ybJoo issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
Cambridge, England (ots/PRNewswire) - Cambridge biotech company Arecor has been awarded GBP785,000 from the government-backed Biomedical Catalyst Fund to accelerate the development of high concentration antibodies to allow more convenient administration of our future therapeutic medicines and reduce healthcare costs. Arecor has recently demonstrated Proof of Concept in ...